查看購物車
  • English
  • Japanese
  • Korean
微流體市場－全球及區域分析：依產品類型、應用、最終用戶與地區分類－分析與預測，2026-2036年
市場調查報告書
商品編碼
2129868

微流體市場－全球及區域分析：依產品類型、應用、最終用戶與地區分類－分析與預測，2026-2036年

Microfluidics Market - A Global and Regional Analysis: Focus on Product Type, Application, End User, and Region - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 138 Pages | 商品交期: 1-5個工作天內

價格

全球微流體市場預計將從2025年的215.8億美元成長到2036年的480.4億美元，預計在2026年至2036年的預測期內，CAGR將達到 7.49%。

關鍵市場統計資料
預測期 2026-2036
2026年市場規模 233.2億美元
2036年的預測 480.4億美元
CAGR 7.49%

全球微流體市場正穩步成長，其成長動力主要來自對快速、微創診斷日益成長的需求、即時檢測和分散式檢查的擴展、基因組和單細胞分析的廣泛應用，以及生物醫學研發中小型化和自動化工作流程的日益普及。醫院、診斷中心、實驗室、生物製藥和生物技術公司以及其他終端用戶利用微流體技術高精度地操控、處理、分析、製備、輸送或監測微量流體。高通量和自動化平台的商業化進程、對專用耗材的持續需求、與定序和數位PCR技術的融合，以及在晶片器官系統、製劑和治療監測等領域不斷擴展的應用，都為該市場的發展提供了支撐。總體而言，該市場正朝著整合、自動化且應用特定的平台和耗材生態系統發展。

市場概覽

全球微流體市場指的是應用於人類醫療保健、生物醫學研究、製藥和生物技術領域的系統、平台和耗材，在這些領域中，微流體技術對於產品功能和工作流程非常重要。這些產品能夠對診斷、分析、研究、製劑和治療工作流程中的微量流體進行可控制的操作、處理、分析或監測。

該市場包括可重複使用的儀器、分析設備和整合平台，這些平台將微尺度流體控制與樣品製備、反應、分離、檢測、成像、自動化和資料採集相結合。它還包括可重複使用的耗材，例如微流體晶片、診斷試劑盒、試劑袋、卡片、奈米板、整合流體迴路、定序流動池、液滴生成試劑盒、器官晶片、內建微流體功能的測試條以及一次性製劑試劑盒和通道。

微流體技術已從專門的實驗室級組件發展成為整合化的商業解決方案，廣泛應用於分子診斷、即時檢測、基因組學、數位PCR、單細胞分析、細胞檢測、藥物製劑、晶片器官研究、控釋治療藥物以及連續或近即時監測等領域。這些系統能夠減少樣品和試劑的消耗，縮短處理時間，支援並行處理，並以緊湊的形式實現多個步驟的自動化。

晶片製造、液滴微流體、高密度陣列、奈米升級反應室、感測器、成像、軟體、自動化流體處理、次世代定序、人工智慧、生物感測器和質譜技術的進步正日益塑造這一市場。該市場的企業著重提高通量、靈敏度、準確性、可重複性、易用性、檢測相容性和可擴展生產能力。隨著醫療保健和生命科學機構不斷增加對分散式診斷、精準醫療、基因組學、單細胞生物學、藥物發現和生物製藥開發的投入，微流體技術有望日益融入常規研究、臨床和商業性工作流程。

對產業的影響

隨著醫療、科研和生物製藥機構對快速、自動化、小批量、高通量工作流程的需求日益成長，微流體在全球市場的應用也日益廣泛。Agilent Technologies, Inc.、Thermo Fisher Scientific Inc.、QIAGEN N.V.、Illumina, Inc.、Revvity, Inc.、Standard BioTools Inc.、Merck KGaA、Randox Laboratories Ltd.、microfluidic ChipShop GmbH、Fluidic Sciences、Danaher Corporation、Abbott、bioMerieux S.A.、10x Genomics、Bio-Rad Laboratories, Inc.等領先企業在推動微流體系統、晶片、晶片盒、整合流體迴路、定序定序池、數位PCR、診斷分析儀、細胞分析平台以及專業開發和製造服務方面發揮著非常重要的作用。

這些技術廣泛應用於體外診斷（IVD）和臨床檢測、基因組學和分子生物學、細胞分析和基於細胞的檢測、微流體控制劑和加工以及治療藥物遞送和監測等領域。微流體技術透過減少所需的樣本和試劑用量、整合多個處理步驟、提高分析精度以及加快檢測結果的獲取，改善了診斷的可及性，提高了研究效率，並支持更大規模的藥物發現和生物製藥工作流程。

市場影響在醫院和診斷中心（最大的終端用戶群）最為顯著，此外，研究機構、學術機構以及生物製藥和生物技術公司也紛紛採用微流體平台進行基因組學、分子診斷、單細胞研究、製劑開發、篩檢和轉化研究。然而，缺乏標準化、高複雜度測試中心數量有限、需要大量資本投入、原型產品難以擴展到商業化生產規模以及監管和驗證要求各異等問題，仍然阻礙著微流控平台的普及應用。

目錄

第1章 全球微流體市場：產業展望

  • 市場概覽與生態系統
    • 介紹
    • 市場上現有微流體解決方案的特點
    • 微流體技術在臨床診斷的應用
    • 全球發展
  • 市場趨勢
    • 趨勢：對當前和未來影響的評估
  • 供應鏈分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機會

第2章 全球微流體市場：依產品類型分類，2024-2036年

  • 微流體系統和平台
    • 市場規模及預測
  • 微流體耗材
    • 市場規模及預測

第3章 全球微流體市場：依應用領域分類，2024-2036年

  • 體外診斷（IVD）和臨床實驗室檢測
    • 市場規模及預測
  • 基因組學與分子生物學
    • 市場規模及預測
  • 細胞分析和基於細胞的檢測
    • 市場規模及預測
  • 用於配方和加工的微流體
    • 市場規模及預測
  • 藥物傳輸和監測
    • 市場規模及預測
  • 其他用途
    • 市場規模及預測

第4章 全球微流體市場：依最終用戶分類，2024-2036年

  • 研究和學術機構
    • 市場規模及預測
  • 生物製藥和生物技術公司
    • 市場規模及預測
  • 醫院和診斷中心
    • 市場規模及預測
  • 其他最終用戶
    • 市場規模及預測

第5章 全球微流體市場：依地區分類，2024-2036年

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 拉丁美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 世界其他地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 業界考察
    • 成長佔有率分析
    • 市場佔有率分析

第6章 競爭標竿分析與公司概況

  • 關鍵策略和趨勢
  • 公司簡介
    • Agilent Technologies, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Illumina, Inc.
    • Revvity, Inc.
    • Standard BioTools Inc.
    • Merck KGaA
    • Randox Laboratories Ltd.
    • microfluidic ChipShop GmbH
    • Fluidic Sciences
    • Danaher Corporation
    • Abbott
    • bioMerieux SA
    • 10x Genomics
    • Bio-Rad Laboratories, Inc.

第7章 調查方法

Product Code: BH00786SB

This report can be delivered within 1 working day.

Introduction of the Microfluidics Market

The global microfluidics market is projected to reach $48.04 billion by 2036 from $21.58 billion in 2025, growing at a CAGR of 7.49% during the forecast period 2026-2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$23.32 Billion
2036 Forecast$48.04 Billion
CAGR7.49%

The global microfluidics market has been experiencing steady growth, driven by increasing demand for rapid and minimally invasive diagnostics, expansion of point-of-care and decentralized testing, growing adoption of genomic and single-cell analysis, and greater use of miniaturized and automated workflows in biomedical research and drug development. Microfluidic technologies are used across hospitals and diagnostic centers, research and academic laboratories, biopharmaceutical and biotechnology companies, and other end users to manipulate, process, analyze, formulate, deliver, or monitor small fluid volumes with high precision. The market is supported by increasing commercialization of high-throughput and automated platforms, recurring demand for proprietary consumables, integration with sequencing and digital PCR, and expanding applications in organ-on-chip systems, formulation, and therapeutic monitoring. Overall, the market is moving toward integrated, automated, application-specific platform-and-consumable ecosystems.

Market Introduction

The global microfluidics market represents the systems, platforms, and consumables used across human healthcare, biomedical research, and pharmaceutical and biotechnology applications where microfluidics is integral to the product's functionality or workflow. These products enable the controlled manipulation, processing, analysis, or monitoring of small fluid volumes across diagnostic, analytical, research, formulation, and therapeutic workflows.

The market includes reusable instruments, analyzers, and integrated platforms that combine microscale fluid control with sample preparation, reaction, separation, detection, imaging, automation, and data acquisition. It also includes recurring consumables such as microfluidic chips, diagnostic cartridges, pouches, cards, nanoplates, integrated fluidic circuits, sequencing flow cells, droplet-generation cartridges, organ-on-chip plates, test strips with integral microfluidics, and single-use formulation cartridges and flow paths.

Microfluidics has evolved from specialized laboratory-scale components toward integrated commercial solutions used in molecular diagnostics, point-of-care testing, genomics, digital PCR, single-cell analysis, cell-based assays, pharmaceutical formulation, organ-on-chip research, controlled therapeutic delivery, and continuous or near-real-time monitoring. These systems reduce sample and reagent consumption, shorten turnaround time, support parallelization, and automate multiple workflow steps within compact formats.

The market is increasingly shaped by advances in chip fabrication, droplet microfluidics, high-density arrays, nanoliter-scale reaction chambers, sensors, imaging, software, automated fluid handling, next-generation sequencing, artificial intelligence, biosensors, and mass spectrometry. Companies operating in the market are focusing on higher throughput, sensitivity, precision, reproducibility, ease of use, assay compatibility, and scalable manufacturing. As healthcare and life science organizations continue to invest in decentralized diagnostics, precision medicine, genomics, single-cell biology, drug discovery, and biopharmaceutical development, microfluidics is expected to become increasingly embedded in routine research, clinical, and commercial workflows.

Industrial Impact

The global microfluidics market has witnessed increasing adoption as healthcare, research, and biopharmaceutical organizations seek rapid, automated, low-volume, and high-throughput workflows. Key players such as Agilent Technologies, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Revvity, Inc., Standard BioTools Inc., Merck KGaA, Randox Laboratories Ltd., microfluidic ChipShop GmbH, Fluidic Sciences, Danaher Corporation, Abbott, bioMerieux S.A., 10x Genomics, and Bio-Rad Laboratories, Inc. play an important role in advancing microfluidic systems, chips, cartridges, integrated fluidic circuits, sequencing flow cells, digital PCR, diagnostic analyzers, cell-analysis platforms, and specialized development and manufacturing services.

These technologies are widely used across IVD and clinical testing, genomics and molecular biology, cell analysis and cell-based assays, microfluidic formulation and processing, and therapeutic delivery and monitoring. By reducing sample and reagent requirements, integrating multiple processing steps, improving analytical precision, and enabling faster turnaround, microfluidics is improving diagnostic access and research productivity while supporting more scalable drug-discovery and biopharmaceutical workflows.

The market's impact is most visible in hospitals and diagnostic centers, which represent the largest end-user segment, and in research and academic laboratories and biopharmaceutical and biotechnology companies adopting microfluidic platforms for genomics, molecular diagnostics, single-cell research, formulation, screening, and translational studies. However, lack of standardization, limited availability of high-complexity testing centers, high capital requirements, challenges in scaling prototypes to commercial production, and differing regulatory and validation requirements continue to influence adoption.

Market Segmentation:

Segmentation 1: By Product Type

  • Microfluidic Systems and Platforms
  • Microfluidic Consumables

Microfluidic Consumables Segment to Dominate the Microfluidics Market (by Product Type)

In 2025, the microfluidic consumables segment accounted for the largest market share, representing approximately 66.7% of the global market. The segment's leadership is driven by recurring use of disposable chips, cartridges, plates, sequencing flow cells, integrated fluidic circuits, diagnostic pouches and cards, droplet-generation cartridges, organ-on-chip plates, and other application-specific consumables across diagnostic testing, life science research, drug discovery, cell analysis, genomics, and pharmaceutical workflows. Microfluidic consumables are also expected to register the higher CAGR of 7.67% from 2026 to 2036, compared with 7.14% for microfluidic systems and platforms, supported by the expanding installed base of instruments and the recurring replacement requirements of proprietary formats.

Segmentation 2: By Application

  • IVD and Clinical Testing
  • Genomics and Molecular Biology
  • Cell Analysis and Cell-Based Assays
  • Microfluidic Formulation and Processing
  • Therapeutic Delivery and Monitoring
  • Other Applications

IVD and Clinical Testing Segment to Dominate the Microfluidics Market (by Application)

In 2025, the IVD and clinical testing segment accounted for the largest market share of the global microfluidics market. Its leadership is supported by extensive use of microfluidic technologies in molecular diagnostics, point-of-care testing, immunoassays, clinical chemistry, infectious disease testing, and other diagnostic workflows. Microfluidic systems can reduce sample and reagent requirements, shorten turnaround time, and integrate sample preparation, reaction, and detection across centralized laboratories and decentralized care settings. Therapeutic delivery and monitoring is expected to register the highest CAGR of 9.50% from 2026 to 2036, supported by miniaturized and controlled drug-delivery systems, wearable and implantable monitoring technologies, and platforms enabling precise fluid handling and continuous or near-real-time monitoring.

Segmentation 3: By End User

  • Hospitals and Diagnostic Centers
  • Research and Academic Laboratories
  • Biopharmaceutical and Biotechnology Companies
  • Other End Users

Hospitals and Diagnostic Centers to Dominate the Microfluidics Market (by End User)

In terms of end user, hospitals and diagnostic centers accounted for the largest share of the global microfluidics market in 2025.The segment's leadership is supported by widespread use of microfluidic technologies in point-of-care testing, molecular diagnostics, clinical chemistry, immunoassays, and other routine and specialized diagnostic workflows. Growing demand for rapid testing, smaller sample volumes, shorter turnaround times, and decentralized diagnostic solutions continues to support adoption across hospitals and diagnostic laboratories. Biopharmaceutical and biotechnology companies are expected to register the highest CAGR of 8.53% from 2026 to 2036, driven by increasing use of microfluidics in drug discovery, cell analysis, single-cell research, formulation development, and screening.

Segmentation 4: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Singapore
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Rest-of-the-World

North America to Dominate the Microfluidics Market (by Region)

In terms of region, North America accounted for the largest share of the global microfluidics market in 2025.Its leadership is supported by the strong presence of biotechnology, pharmaceutical, diagnostics, and life science companies; widespread adoption of microfluidic platforms in molecular diagnostics and biomedical research; and substantial investment in advanced healthcare technologies. The U.S. remains the major contributor owing to its established life science research ecosystem, high adoption of point-of-care and molecular diagnostic technologies, and strong presence of leading microfluidics platform and chip manufacturers.

While North America is expected to retain the largest market share, Asia-Pacific is anticipated to register the highest CAGR of 8.72% from 2026 to 2036. Regional growth is supported by increasing healthcare and life science R&D investment, expanding biotechnology and pharmaceutical industries, rising adoption of point-of-care diagnostics, and growing research involving microfluidic technologies across China, Japan, India, Singapore, Australia, and other Asia-Pacific markets.

Recent Developments in the Microfluidics Market

  • In June 2026,10x Genomics and Cleveland Clinic began a multi-year bladder-cancer research collaboration using the Flex Apex and spatial platforms to identify biomarkers associated with treatment response and support future diagnostic development.
  • In June 2026, Abbott received U.S. FDA 510(k) clearance for the i-STAT hs-TnI cartridge with the i-STAT Alinity System, extending its single-use cartridge-based high-sensitivity cardiac troponin testing to the newer handheld platform.
  • In January 2026, Cepheid received U.S. FDA clearance for the Xpert GI Panel, a single-use GeneXpert cartridge that detects 11 gastrointestinal pathogens using 10-color multiplex PCR.
  • In January 2026,10x Genomics and CareDx established the ImmuneScape research program, using the microfluidic Chromium Flex single-cell platform with spatial technologies to study transplant rejection and therapeutic response.
  • In December 2025, Thermo Fisher Scientific Inc. collaborated with AIM Biotech to develop standardized microphysiological systems combining AIM Biotech's organiX and VasQ microfluidic platforms with Thermo Fisher Scientific Inc.'s tumoroid models, culture media, and supporting reagents.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Growing Demand for Non-Invasive and Rapid Diagnosis: The growing need for rapid, minimally invasive, and patient-friendly diagnostic approaches is a major driver for the global microfluidics market. Conventional diagnostic workflows often depend on centralized laboratories, relatively large sample volumes, trained personnel, and multiple processing steps. Microfluidic platforms address several of these limitations by manipulating very small volumes of biological fluids and integrating sample preparation, separation, reaction, and detection within compact devices. This supports faster turnaround and expands the feasibility of point-of-care and decentralized testing. Increasing interest in non-invasive samples such as saliva, sweat, urine, and tears is also broadening the application base for microfluidic diagnostics and wearable monitoring.

Market Challenges

Lack of Standardization: The absence of uniform standards across chip materials, dimensions, fabrication processes, fluidic interfaces, connectors, assay protocols, and performance-validation methods remains a major restraint. Variation among proprietary platforms can limit interoperability, complicate integration with existing laboratory infrastructure, and increase development and validation requirements. It also makes it more difficult to transfer laboratory prototypes into reproducible, high-volume commercial production, increasing commercialization timelines and costs.

Market Opportunities

Massive Scope for Adoption of Microfluidics-Based Solutions in Emerging Nations: Emerging markets present a significant opportunity for microfluidic technologies because compact, low-volume, and potentially portable platforms can help expand access to diagnostics and biomedical testing where centralized laboratory infrastructure and specialist capacity are limited. Growing healthcare investment, expanding biotechnology and pharmaceutical activity, increasing infectious and chronic disease testing needs, and demand for point-of-care solutions are creating opportunities for affordable, robust, easy-to-use microfluidic systems and consumables. Vendors that combine scalable manufacturing with localized distribution, technical support, clinical validation, and regulatory strategies are expected to be better positioned to capture this opportunity.

How can this report add value to an organization?

Product/Innovation Strategy: The global microfluidics market has been divided into several key segments, including product type, application, end user, and regional markets. By understanding demand across microfluidic systems and platforms, microfluidic consumables, IVD and clinical testing, genomics and molecular biology, cell analysis and cell-based assays, microfluidic formulation and processing, and therapeutic delivery and monitoring, this report offers valuable insights for organizations seeking to refine their product and innovation strategies.

Growth/Marketing Strategy: Expansion of rapid and minimally invasive diagnostics, point-of-care testing, personalized medicine, genomics, single-cell analysis, organ-on-chip research, pharmaceutical formulation, therapeutic delivery, and automated high-throughput workflows is anticipated to be central to the growth of the microfluidics market. Key developments among microfluidic platform providers, diagnostic companies, sequencing companies, research institutions, and biopharmaceutical organizations are shaping adoption across clinical, research, and commercial environments.

Competitive Strategy: The microfluidics market is competitive and technology-driven, with established diagnostics and life science companies, specialized platform developers, chip manufacturers, and microfluidic development and manufacturing organizations competing through throughput, automation, sensitivity, precision, assay compatibility, workflow integration, recurring consumables, scalable production, and regulatory validation. Key market players are strengthening their positions through product launches and upgrades, platform-and-consumable ecosystems, partnerships, acquisitions, application-specific development, and integration with sequencing, imaging, artificial intelligence, biosensors, and other analytical technologies.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts across various sectors, including microfluidic systems and platform providers, microfluidic consumables manufacturers, diagnostic companies, sequencing and digital PCR companies, hospitals and diagnostic centers, research and academic laboratories, and biopharmaceutical and biotechnology companies.
  • Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates have been derived from primary research inputs, funding history, market collaborations, product portfolios, and operational performance.
  • The market has been mapped based on existing microfluidic systems, platforms, and consumables in which microfluidics is integral to product functionality or workflow. Key companies with significant offerings in microfluidic diagnostics, genomics, cell analysis, formulation, therapeutic delivery, and supporting chip-development and manufacturing capabilities have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts from the healthcare, life sciences, diagnostics, and biopharmaceutical industries and various stakeholders, such as microfluidic system and platform providers, chip and consumables manufacturers, diagnostic companies, sequencing and digital PCR companies, specialized microfluidic development and manufacturing organizations, hospitals and diagnostic centers, research and academic laboratories, and biopharmaceutical and biotechnology companies. Respondents such as CEOs, vice presidents, marketing directors, product managers, laboratory directors, research scientists, engineers, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Illumina, Inc.
  • Revvity, Inc.
  • Standard BioTools Inc.
  • Merck KGaA
  • Randox Laboratories Ltd.
  • microfluidic ChipShop GmbH
  • Fluidic Sciences
  • Danaher Corporation
  • Abbott
  • bioMerieux S.A.
  • 10x Genomics
  • Bio-Rad Laboratories, Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Global Microfluidics Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
    • 1.1.1 Introduction
    • 1.1.2 Characteristics of Market-Available Microfluidics Solutions
    • 1.1.3 Microfluidics in Clinical Diagnostics
    • 1.1.4 Global Footprint
  • 1.2 Market Trends
    • 1.2.1 Trends: Current and Future Impact Assessment
      • 1.2.1.1 Impact Analysis
        • 1.2.1.1.1 Increasing Commercialization of High-Throughput and Automated Microfluidic Platforms
  • 1.3 Supply Chain Analysis
  • 1.4 Market Dynamics
    • 1.4.1 Market Drivers
      • 1.4.1.1 Growing Demand for Non-Invasive and Rapid Diagnosis
      • 1.4.1.2 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
      • 1.4.1.3 Significant External Funding for Executing Research and Development Exercises
      • 1.4.1.4 Growing Demand for Point-of-Care Diagnostics
    • 1.4.2 Market Restraints
      • 1.4.2.1 Lack of Standardization
      • 1.4.2.2 Lack of High Complexity Testing Centers
      • 1.4.2.3 High Capital Requirement Hampering the Expansion of Global Reach
    • 1.4.3 Market Opportunities
      • 1.4.3.1 Massive Scope for Adoption of Microfluidics-based Solutions in Emerging Nations
      • 1.4.3.2 Increased Use of Microfluidics in Widespread Applications
      • 1.4.3.3 Hybridization of Technologies

2 Global Microfluidics Market (by Product Type), $Million, 2024-2036

  • 2.1 Microfluidic Systems and Platforms
    • 2.1.1 Market Sizing and Forecast
  • 2.2 Microfluidic Consumables
    • 2.2.1 Market Sizing and Forecast

3 Global Microfluidics Market (by Application), $Billion, 2024-2036

  • 3.1 IVD and Clinical Testing
    • 3.1.1 Market Sizing and Forecast
  • 3.2 Genomics and Molecular Biology
    • 3.2.1 Market Sizing and Forecast
  • 3.3 Cell Analysis and Cell-Based Assays
    • 3.3.1 Market Sizing and Forecast
  • 3.4 Microfluidic Formulation and Processing
    • 3.4.1 Market Sizing and Forecast
  • 3.5 Therapeutic Delivery and Monitoring
    • 3.5.1 Market Sizing and Forecast
  • 3.6 Other Applications
    • 3.6.1 Market Sizing and Forecast

4 Global Microfluidics Market (by End User), $Billion, 2024-2036

  • 4.1 Research and Academic Laboratories
    • 4.1.1 Market Sizing and Forecast
  • 4.2 Biopharmaceutical and Biotech Companies
    • 4.2.1 Market Sizing and Forecast
  • 4.3 Hospitals and Diagnostic Centers
    • 4.3.1 Market Sizing and Forecast
  • 4.4 Other End Users
    • 4.4.1 Market Sizing and Forecast

5 Global Microfluidics Market (by Region), $Billion, 2024-2036

  • 5.1 Regional Summary
  • 5.2 North America
    • 5.2.1 Regional Overview
    • 5.2.2 Driving Factors for Market Growth
    • 5.2.3 Factors Challenging the Market
    • 5.2.4 Analyst View
    • 5.2.5 Market Sizing and Forecast
      • 5.2.5.1 North America Microfluidics Market, by Country
        • 5.2.5.1.1 U.S.
          • 5.2.5.1.1.1 Country Overview
          • 5.2.5.1.1.2 Driving Factors for Market Growth
          • 5.2.5.1.1.3 Factors Challenging the Market
          • 5.2.5.1.1.4 Analyst View
          • 5.2.5.1.1.5 Market Sizing and Forecast
        • 5.2.5.1.2 Canada
          • 5.2.5.1.2.1 Country Overview
          • 5.2.5.1.2.2 Driving Factors for Market Growth
          • 5.2.5.1.2.3 Factors Challenging the Market
          • 5.2.5.1.2.4 Analyst View
          • 5.2.5.1.2.5 Market Sizing and Forecast
  • 5.3 Europe
    • 5.3.1 Regional Overview
    • 5.3.2 Driving Factors for Market Growth
    • 5.3.3 Factors Challenging the Market
    • 5.3.4 Analyst View
    • 5.3.5 Market Sizing and Forecast
      • 5.3.5.1 Europe Microfluidics Market, by Country
        • 5.3.5.1.1 Germany
          • 5.3.5.1.1.1 Country Overview
          • 5.3.5.1.1.2 Driving Factors for Market Growth
          • 5.3.5.1.1.3 Factors Challenging the Market
          • 5.3.5.1.1.4 Analyst View
          • 5.3.5.1.1.5 Market Sizing and Forecast
        • 5.3.5.1.2 France
          • 5.3.5.1.2.1 Country Overview
          • 5.3.5.1.2.2 Driving Factors for Market Growth
          • 5.3.5.1.2.3 Factors Challenging the Market
          • 5.3.5.1.2.4 Analyst View
          • 5.3.5.1.2.5 Market Sizing and Forecast
        • 5.3.5.1.3 U.K.
          • 5.3.5.1.3.1 Country Overview
          • 5.3.5.1.3.2 Driving Factors for Market Growth
          • 5.3.5.1.3.3 Factors Challenging the Market
          • 5.3.5.1.3.4 Analyst View
          • 5.3.5.1.3.5 Market Sizing and Forecast
        • 5.3.5.1.4 Italy
          • 5.3.5.1.4.1 Country Overview
          • 5.3.5.1.4.2 Driving Factors for Market Growth
          • 5.3.5.1.4.3 Factors Challenging the Market
          • 5.3.5.1.4.4 Analyst View
          • 5.3.5.1.4.5 Market Sizing and Forecast
        • 5.3.5.1.5 Spain
          • 5.3.5.1.5.1 Country Overview
          • 5.3.5.1.5.2 Driving Factors for Market Growth
          • 5.3.5.1.5.3 Factors Challenging the Market
          • 5.3.5.1.5.4 Analyst View
          • 5.3.5.1.5.5 Market Sizing and Forecast
        • 5.3.5.1.6 Rest-of-Europe
          • 5.3.5.1.6.1 Country Overview
          • 5.3.5.1.6.2 Driving Factors for Market Growth
          • 5.3.5.1.6.3 Factors Challenging the Market
          • 5.3.5.1.6.4 Analyst View
          • 5.3.5.1.6.5 Market Sizing and Forecast
  • 5.4 Asia-Pacific
    • 5.4.1 Regional Overview
    • 5.4.2 Driving Factors for Market Growth
    • 5.4.3 Factors Challenging the Market
    • 5.4.4 Analyst View
    • 5.4.5 Market Sizing and Forecast
      • 5.4.5.1 Asia-Pacific Microfluidics Market, by Country
      • 5.4.5.2 China
        • 5.4.5.2.1 Country Overview
        • 5.4.5.2.2 Driving Factors for Market Growth
        • 5.4.5.2.3 Factors Challenging the Market
        • 5.4.5.2.4 Analyst View
        • 5.4.5.2.5 Market Sizing and Forecast
      • 5.4.5.3 India
        • 5.4.5.3.1 Country Overview
        • 5.4.5.3.2 Driving Factors for Market Growth
        • 5.4.5.3.3 Factors Challenging the Market
        • 5.4.5.3.4 Analyst View
        • 5.4.5.3.5 Market Sizing and Forecast
      • 5.4.5.4 Japan
        • 5.4.5.4.1 Country Overview
        • 5.4.5.4.2 Driving Factors for Market Growth
        • 5.4.5.4.3 Factors Challenging the Market
        • 5.4.5.4.4 Analyst View
        • 5.4.5.4.5 Market Sizing and Forecast
      • 5.4.5.5 Singapore
        • 5.4.5.5.1 Country Overview
        • 5.4.5.5.2 Driving Factors for Market Growth
        • 5.4.5.5.3 Factors Challenging the Market
        • 5.4.5.5.4 Analyst View
        • 5.4.5.5.5 Market Sizing and Forecast
      • 5.4.5.6 Australia
        • 5.4.5.6.1 Country Overview
        • 5.4.5.6.2 Driving Factors for Market Growth
        • 5.4.5.6.3 Factors Challenging the Market
        • 5.4.5.6.4 Analyst View
        • 5.4.5.6.5 Market Sizing and Forecast
      • 5.4.5.7 Rest-of-Asia-Pacific
        • 5.4.5.7.1 Country Overview
        • 5.4.5.7.2 Driving Factors for Market Growth
        • 5.4.5.7.3 Factors Challenging the Market
        • 5.4.5.7.4 Analyst View
        • 5.4.5.7.5 Market Sizing and Forecast
  • 5.5 Latin America
    • 5.5.1 Regional Overview
    • 5.5.2 Driving Factors for Market Growth
    • 5.5.3 Factors Challenging the Market
    • 5.5.4 Analyst View
    • 5.5.5 Market Sizing and Forecast
      • 5.5.5.1 Latin America Microfluidics Market, by Country
      • 5.5.5.2 Brazil
        • 5.5.5.2.1 Country Overview
        • 5.5.5.2.2 Driving Factors for Market Growth
        • 5.5.5.2.3 Factors Challenging the Market
        • 5.5.5.2.4 Analyst View
        • 5.5.5.2.5 Market Sizing and Forecast
      • 5.5.5.3 Mexico
        • 5.5.5.3.1 Country Overview
        • 5.5.5.3.2 Driving Factors for Market Growth
        • 5.5.5.3.3 Factors Challenging the Market
        • 5.5.5.3.4 Analyst View
        • 5.5.5.3.5 Market Sizing and Forecast
      • 5.5.5.4 Rest-of-Latin America
        • 5.5.5.4.1 Country Overview
        • 5.5.5.4.2 Driving Factors for Market Growth
        • 5.5.5.4.3 Factors Challenging the Market
        • 5.5.5.4.4 Analyst View
        • 5.5.5.4.5 Market Sizing and Forecast
  • 5.6 Rest-of-the-World
    • 5.6.1 Regional Overview
    • 5.6.2 Driving Factors for Market Growth
    • 5.6.3 Factors Challenging the Market
    • 5.6.4 Analyst View
    • 5.6.5 Market Sizing and Forecast
  • 5.7 Industry Insights
    • 5.7.1 Growth Share Analysis
    • 5.7.2 Market Share Analysis

6 Competitive Benchmarking and Company Profiles

  • 6.1 Key Strategies and Developments
  • 6.2 Company Profiles
    • 6.2.1 Agilent Technologies, Inc.
      • 6.2.1.1 Overview
      • 6.2.1.2 Top Products
      • 6.2.1.3 Role of Agilent Technologies, Inc. in the Global Microfluidics Market
      • 6.2.1.4 Financials
      • 6.2.1.5 Key Insights About Financial Health of the Company
      • 6.2.1.6 SWOT Analysis
    • 6.2.2 Thermo Fisher Scientific Inc.
      • 6.2.2.1 Overview
      • 6.2.2.2 Top Products
      • 6.2.2.3 Role of Thermo Fisher Scientific Inc. in the Global Microfluidics Market
      • 6.2.2.4 Financials
      • 6.2.2.5 Key Insights About Financial Health of the Company
      • 6.2.2.6 SWOT Analysis
    • 6.2.3 QIAGEN N.V.
      • 6.2.3.1 Overview
      • 6.2.3.2 Top Products
      • 6.2.3.3 Role of QIAGEN N.V. in the Global Microfluidics Market
      • 6.2.3.4 Financials
      • 6.2.3.5 Key Insights About Financial Health of the Company
      • 6.2.3.6 SWOT Analysis
    • 6.2.4 Illumina, Inc.
      • 6.2.4.1 Overview
      • 6.2.4.2 Top Products
      • 6.2.4.3 Role of Illumina, Inc. in the Global Microfluidics Market
      • 6.2.4.4 Financials
      • 6.2.4.5 Key Insights About Financial Health of the Company
      • 6.2.4.6 SWOT Analysis
    • 6.2.5 Revvity, Inc.
      • 6.2.5.1 Overview
      • 6.2.5.2 Top Products
      • 6.2.5.3 Role of Revvity in the Global Microfluidics Market
      • 6.2.5.4 Financials
      • 6.2.5.5 Key Insights About Financial Health of the Company
      • 6.2.5.6 SWOT Analysis
    • 6.2.6 Standard BioTools Inc.
      • 6.2.6.1 Overview
      • 6.2.6.2 Top Products
      • 6.2.6.3 Role of Standard BioTools Inc. in the Global Microfluidics Market
      • 6.2.6.4 Financials
      • 6.2.6.5 Key Insights About Financial Health of the Company
      • 6.2.6.6 SWOT Analysis
    • 6.2.7 Merck KGaA
      • 6.2.7.1 Overview
      • 6.2.7.2 Top Products
      • 6.2.7.3 Role of Merck KGaA in the Global Microfluidics Market
      • 6.2.7.4 Financials
      • 6.2.7.5 Key Insights About Financial Health of the Company
      • 6.2.7.6 SWOT Analysis
    • 6.2.8 Randox Laboratories Ltd.
      • 6.2.8.1 Overview
      • 6.2.8.2 Top Products
      • 6.2.8.3 Role of Randox Laboratories Ltd. in the Global Microfluidics Market
      • 6.2.8.4 SWOT Analysis
    • 6.2.9 microfluidic ChipShop GmbH
      • 6.2.9.1 Overview
      • 6.2.9.2 Top Products
      • 6.2.9.3 Role of microfluidic ChipShop GmbH in the Global Microfluidics Market
      • 6.2.9.4 SWOT Analysis
    • 6.2.10 Fluidic Sciences
      • 6.2.10.1 Overview
      • 6.2.10.2 Top Products
      • 6.2.10.3 Role of Fluidic Sciences in the Global Microfluidics Market
      • 6.2.10.4 SWOT Analysis
    • 6.2.11 Danaher Corporation
      • 6.2.11.1 Overview
      • 6.2.11.2 Top Products
      • 6.2.11.3 Role of Danaher Corporation in the Global Microfluidics Market
      • 6.2.11.4 Financials
      • 6.2.11.5 Key Insights About Financial Health of the Company
      • 6.2.11.6 SWOT Analysis
    • 6.2.12 Abbott
      • 6.2.12.1 Overview
      • 6.2.12.2 Top Products
      • 6.2.12.3 Role of Abbott in the Global Microfluidics Market
      • 6.2.12.4 Financials
      • 6.2.12.5 Key Insights About Financial Health of the Company
      • 6.2.12.6 SWOT Analysis
    • 6.2.13 bioMerieux S.A.
      • 6.2.13.1 Overview
      • 6.2.13.2 Top Products
      • 6.2.13.3 Role of BIOMERIEUX in the Global Microfluidics Market
      • 6.2.13.4 Financials
      • 6.2.13.5 Key Insights About Financial Health of the Company
      • 6.2.13.6 SWOT Analysis
      • 6.2.13.7 Analyst View
    • 6.2.14 10x Genomics
      • 6.2.14.1 Overview
      • 6.2.14.2 Top Products
      • 6.2.14.3 Role of 10x Genomics in the Global Microfluidics Market
      • 6.2.14.4 Financials
      • 6.2.14.5 Key Insights About Financial Health of the Company
      • 6.2.14.6 SWOT Analysis
    • 6.2.15 Bio-Rad Laboratories, Inc.
      • 6.2.15.1 Overview
      • 6.2.15.2 Top Products
      • 6.2.15.3 Role of Bio-Rad Laboratories, Inc. in the Global Microfluidics Market
      • 6.2.15.4 Financials
      • 6.2.15.5 Key Insights About Financial Health of the Company
      • 6.2.15.6 SWOT Analysis

7 Research Methodology

  • 7.1 Data Sources
    • 7.1.1 Primary Data Sources
    • 7.1.2 Secondary Data Sources
    • 7.1.3 Data Triangulation
  • 7.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Microfluidics Market (by Scenario), $Billion, 2026, 2031, and 2036
  • Figure 2: Global Microfluidics Market (by Region), $Billion, 2025, 2031, 2036
  • Figure 3: Global Microfluidics Market (by Product Type), $Billion, 2025, 2031, and 2036
  • Figure 4: Global Microfluidics Market (by Application), $Billion, 2025, 2031, and 2036
  • Figure 5: Global Microfluidics Market (by End User), $Billion, 2025, 2031, and 2036
  • Figure 6: Supply Chain Analysis
  • Figure 7: Global Microfluidics Market (by Product Type), $Billion, 2025, 2031, and 2036
  • Figure 8: Global Microfluidics Market (Microfluidic Systems and Platforms), $Billion, 2024-2036
  • Figure 9: Global Microfluidics Market (Microfluidic Consumables), $Billion, 2024-2036
  • Figure 10: Global Microfluidics Market (by Application), $Billion, 2025, 2031, and 2036
  • Figure 11: Global Microfluidics Market (IVD and Clinical Testing), $Billion, 2024-2036
  • Figure 12: Global Microfluidics Market (Genomics and Molecular Biology), $Billion, 2024-2036
  • Figure 13: Global Microfluidics Market (Cell Analysis and Cell-Based Assays), $Billion, 2024-2036
  • Figure 14: Global Microfluidics Market (Microfluidic Formulation and Processing), $Billion, 2024-2036
  • Figure 15: Global Microfluidics Market (Therapeutic Delivery and Monitoring), $Billion, 2024-2036
  • Figure 16: Global Microfluidics Market (Other Applications), $Billion, 2024-2036
  • Figure 17: Global Microfluidics Market (by End User), $Billion, 2025, 2031, and 2036
  • Figure 18: Global Microfluidics Market, (Research and Academic Laboratories), $Billion, 2024-2036
  • Figure 19: Global Microfluidics Market, (Biopharmaceutical and Biotech Companies), $Billion, 2024-2036
  • Figure 20: Global Microfluidics Market, (Hospitals and Diagnostic Centers), $Billion, 2024-2036
  • Figure 21: Global Microfluidics Market, (Other End Users), $Billion, 2024-2036
  • Figure 22: North America Microfluidics Market, $Billion, 2024-2036
  • Figure 23: U.S. Microfluidics Market, $Billion, 2024-2036
  • Figure 24: Canada Microfluidics Market, $Billion, 2024-2036
  • Figure 25: Europe Microfluidics Market, $Billion, 2024-2036
  • Figure 26: Germany Microfluidics Market, $Billion, 2024-2036
  • Figure 27: France Microfluidics Market, $Billion, 2024-2036
  • Figure 28: U.K. Microfluidics Market, $Billion, 2024-2036
  • Figure 29: Italy Microfluidics Market, $Billion, 2024-2036
  • Figure 30: Spain Microfluidics Market, $Billion, 2024-2036
  • Figure 31: Rest-of-Europe Microfluidics Market, $Billion, 2024-2036
  • Figure 32: Asia-Pacific Microfluidics Market, $Billion, 2024-2036
  • Figure 33: China Microfluidics Market, $Billion, 2024-2036
  • Figure 34: India Microfluidics Market, $Billion, 2024-2036
  • Figure 35: Japan Microfluidics Market, $Billion, 2024-2036
  • Figure 36: Singapore Microfluidics Market, $Billion, 2024-2036
  • Figure 37: Australia Microfluidics Market, $Billion, 2024-2036
  • Figure 38: Rest-of-Asia-Pacific Microfluidics Market, $Billion, 2024-2036
  • Figure 39: Latin America Microfluidics Market, $Billion, 2024-2036
  • Figure 40: Brazil Microfluidics Market, $Billion, 2024-2036
  • Figure 41: Mexico Microfluidics Market, $Billion, 2024-2036
  • Figure 42: Rest-of-Latin America Microfluidics Market, $Billion, 2024-2036
  • Figure 43: Rest-of-the-World Microfluidics Market, $Billion, 2024-2036
  • Figure 44: Growth-Share Analysis for Global Microfluidics Market (by Product Type), Market Share, 2025 vs. CAGR, 2026-2036.
  • Figure 45: Growth-Share Analysis for Global Microfluidics Market (by Application), Market Share, 2025 vs. CAGR, 2026-2036.
  • Figure 46: Data Triangulation
  • Figure 47: Top-Down and Bottom-Up Approach
  • Figure 48: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • Table 3: Global Microfluidics Market (by Region), $Billion, 2024-2036
  • Table 4: North America Microfluidics Market (by Country), $Billion, 2024-2036
  • Table 5: Europe Microfluidics Market (by Country), $Billion, 2024-2036
  • Table 6: Asia-Pacific Microfluidics Market (by Country), $Billion, 2024-2036
  • Table 7: Latin America Microfluidics Market (by Country), $Billion, 2024-2036
  • Table 8: Global Market Share, 2025
  • Table 9: Some of the Major Key Strategies, December 2025-June 2026